[Incidence and clinical relevance of cytomegalovirus diseases using cyclosporine compared to conventional immunosuppression].
Since transplanted patients have been treated with cyclosporin A after kidney transplantation, the whole immunosuppression has changed. Combined with the specific T-cell suppression, steroids were administered in much lower concentrations. ALG and ATG combined with cyclosporin were avoided because of the immunoproliferative syndrome. Changing in immunosuppression reduced the incidence of CMV-infections from 4.3% to 3.1% in our center. Beside the apparent infection, severe illness was significantly reduced. Under conventional immunosuppression, in 1.7% a loss of transplantate could be observed. This was not the case under cyclosporin A. Since half a year the immunosuppression has changed and triple drug usage was common in high responder patients. It seems that CMV-infections will become more relevant than in former days. Important for us is the recognition of risk groups at the point of transplantation. In these patients a passive vaccination with CMV-hyperimmunoglobulin should be performed.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation
D000305:Adrenal Cortex Hormones; D003524:Cyclosporins; D001379:Azathioprine
Häufigkeit und klinische Relevanz von CMV-Erkrankungen unter Cyclosporin im Gegensatz zur konventionellen Immunsuppression.